LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...

Add Yahoo as a preferred source to see more of our stories on Google. Sodiq Ajibade, 29, who suffers from bouts of asthma attacks, speaks to a pharmacist about the Seretide inhaler at a pharmacy in ...